Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Zydus Lifesciences

Growth unavailable

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, unaudited, with limited review; quarter values from the signed results statement

Reported revenue (₹ million, except EPS in ₹): 79,096

Read summary and comparison caveats

Zydus Lifesciences reported consolidated September-quarter revenue from operations of ₹79,096 million, compared with ₹61,232 million a year earlier. Net profit after non-controlling interests was ₹9,255 million versus the updated comparison of ₹12,609 million. Profit before tax was ₹12,617 million and included net exceptional income of ₹13 million. These figures retain the statement's million-rupee units.

  • Figures are from the company-hosted 16-page signed statement dated 4 Nov 2026, read in full on 17 Nov. The consolidated table and exceptional-item notes were visually checked. This is unaudited information subject to limited review, not an audited quarter. Half-year and standalone figures are not mixed into the table.
  • The filing uses INR million. Amounts here remain in ₹ million, not ₹ crore; ten million rupees equals one crore rupees. EPS is in rupees per share and is not annualised. Only the printed current-quarter and same-quarter-last-year values are shown; no growth rates are calculated.
  • The ₹9,255 million net profit is after ₹22 million of non-controlling interests. The ₹9,277 million profit before those interests is a different measure. In the comparison quarter, non-controlling interests were negative ₹200 million, giving net profit after those interests of ₹12,609 million.
  • Net exceptional income of ₹13 million comprises a ₹396 million provision for rain-related asset damage, offset by ₹376 million of insurance claims receivable and a ₹33 million reversal of severance provision at Assertio. The prior-year quarter had ₹342 million of exceptional expenses. These are the pre-tax items in Note 4, not an adjusted-PAT calculation.
  • Note 13 says purchase-price-allocation finalisation for Amplitude updated prior-period net profit. The September 2025 comparator used here is ₹12,609 million, rather than the previously reported ₹12,586 million. The filing also updates the June 2026 comparator, which is not used here.
  • Note 5 flags tax comparability: the parent recognised a ₹515 million deferred-tax remeasurement gain in the March 2026 quarter, and a subsidiary has MAT-credit adjustments in earlier periods. The filing states current-period tax expenses are not comparable with previous reported periods. Acquisitions also change group scope: results include Comfort Click from 29 Aug 2025, Amplitude from 29 Jul 2025, Agenus facilities from 15 Jan 2026 and Assertio from 16 Jun 2026; this is not a like-for-like organic-growth table.
  • The limited-review report relies on other auditors for some subsidiaries and management-certified unreviewed information for others and joint ventures; it states its conclusion is not modified for those matters. The source document and notes remain necessary for the full context.

Checked 17 Nov 2026

Open original filing
Read the complete published results desk